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Selenium, selenoproteins and
neurodegenerative diseases
Ba´rbara Rita Cardoso,*ab Blaine R. Roberts,a Ashley I. Bush†a and
Dominic J. Hare†*acd
It is unsurprising that our understanding of the role of selenium in neurological function is somewhat
immature, considering its relatively recent discovery as an essential element to human health.
Selenocysteine, the 21st amino acid, is the defining feature of the 25 selenoprotein-encoding genes so
far discovered within the human genome. The low abundance of these proteins in the brain belies the
integral role they play in normal neurological function, from well-characterised antioxidant activity in the
periphery to poorly understood mechanisms that modulate mitochondrial function and response to
brain pathology. Selenium has been identified as playing a role in several neurodegenerative disorders,
including Alzheimer’s and Parkinson’s disease, though its function as a ‘cause or eﬀect’ of disease
process remains unclear. This review discusses selenium metabolism in detail, specifically with regard to
the role it plays within the central nervous system, and examines the most current literature investigating
how selenium may be involved in chronic diseases of the central nervous system.
Introduction
The observation that selenium (Se) prevented necrotic liver
damage in mice by Schwarz and Foltz in 1957 was the first
direct experimental evidence that this element was essential to
normal health.1 Almost twenty years later, Flohe et al.2 con-
firmed the importance of Se by identifying it as an essential
cofactor of glutathione peroxidase (GPx). Twenty-five mamma-
lian selenoprotein-encoding genes have since been identified,3
all containing selenocysteine (Sec) residues, which are analo-
gous to cysteine (Cys) with a selenol moiety replacing the thiol
group.4 From these genes, it is estimated that more than 30 unique
selenoproteins are synthesised in mammals,5 and it is likely more
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will be characterised in the future. Selenoproteins have diverse
roles throughout the body, acting as antioxidants, modulators
of immune function, detoxification agents for heavy metals and
xenobiotics, and participants in thyroid hormone metabolism.6
Selenium is essential to human health, and the antioxidant
activity (or lack thereof) of specific selenoproteins is of parti-
cular interest in diseases of the central nervous system. The
brain is the most metabolically active of all organs in the body,
and although it represents only 2% of the total mass, cerebral
metabolism accounts for about 20% of the oxygen and 25%
of the glucose consumed by the human body.7 In concert with
this high metabolic activity, the high concentration of poly-
unsaturated fatty acids in the brain makes it more vulnerable to
peroxidation. A selective vulnerability within certain neurons
to oxidative stress may arise from deficiencies in antioxidant
enzyme activity,8 which is a likely upstream event in the
pathogenesis of several neurodegenerative diseases,9 including
Alzheimer’s disease (AD),10 Parkinson’s disease (PD)11 and
other neurodegenerative disorders. Selenoproteins, with their
inherent antioxidant activity, thus play essential roles as part of
the free radical defence system, though the function of these
proteins is not necessarily restricted to this singular classifica-
tion. This review summarises the current data and important
concepts concerning selenoproteins on brain function and the
association between Se and diseases of the brain.
Selenoprotein synthesis
Dietary Se first must be converted to selenide (Se2), which
serves as the donor for the incorporation of Se into seleno-
proteins. Inorganic Se forms, such as selenite (SeO3
2), are
converted to Se2 via the glutathione–glutaredoxin and thio-
redoxin pathways, while organic forms are metabolised to Se2
by selenocysteine lyase (Scly) or trans-selenation (analogous to
trans-sulfuration).12
The incorporation of Se into proteins was described in detail
by Turanov et al.,13 recently reviewed by Labunskyy et al.,14 and
is summarised in Fig. 1. After conversion of dietary Se to Se2,
selenophosphate (SePO3
3) is produced in a reaction catalysed
by selenophosphate synthase 2.4 Selenocysteine (Sec) is incor-
porated into proteins via its own unique tRNA, (tRNA[Ser]Sec).
tRNA[Ser]Sec decodes the UGA codon as Sec instead of a stop
codon, as is typical of other amino acids, and thus prevents
premature termination. This is possible due to the presence of
a Sec insertion sequence (SECIS) element, a specific cis-acting
stem-loop structure, in the 30-untranslated region (UTR) of
selenoprotein mRNA that works as a platform for RNA-binding
proteins. SECIS forms complexes with two trans-acting elements:
the specific elongation factor (EFsec) and the SECIS binding
protein 2 (SBP2).15 EFsec interacts with SBP2 to recruit tRNA[Ser]Sec
and mediates insertion of Sec into nascent protein chains in
response to the UGA codon.15 Among the three distinct
domains of SBP2, the Sec incorporation domain and a COOH-
terminal RNA-binding domain are specifically involved in
SECIS binding. Additional SECIS binding proteins have been
identified, including ribosomal L30, which is part of the
basal Sec insertion machinery and has a similar RNA-binding
domain to SBP2;16 a eukaryotic initiation factor (eIF4a3) that
links Se status and diﬀerential selenoprotein expression,17 and
nucleolin, which demonstrates a high aﬃnity for SECIS, though
its complete function is not currently known.18 Recently,
Bro¨cker et al.19 used Escherichia coli formate dehydrogenase
mutants to reassign 64 codons encoding a critical Sec residue,
finding that 58 of these were able to site-specifically incorporate
Sec. At 15 sense codons selenoprotein synthesis could be
promoted compared to the 3 stop codons. This study provides
critical new information about how selenoprotein production
can be manipulated through genetic recoding, and provides
exciting new opportunities for additional studies to further
elucidate the mechanisms involved in selenoprotein synthesis,
which remains a relatively new frontier in molecular biology.
It is known that selenoprotein synthesis is critical for
viability of life, as shown by tRNA[Ser]Sec (Trsp) knockout mice,
which present an embryonically lethal phenotype. However,
Trsp null mice allow tissue-specific manipulation of tRNA[Ser]Sec,
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and this model has been used to investigate the importance of
selenoprotein synthesis to brain metabolism. Wirth et al.20
showed that inactivation of selenoprotein synthesis in Trsp null
neurons abolished the developmental appearance of parvalbumin-
positive (PV) interneuron cells, characterising progressive neuro-
degeneration. This was later confirmed by additional studies
that demonstrated this damage was restricted to specific brain
areas, such as the somatosensory cortex and hippocampus,
confirming the essential requirement of selenoprotein synthesis
formaintenance of CNSmetabolism.21,22 In humans, twomutations
in the gene encoding O-phosphoseryl-tRNA[Sec]:selenocysteinyl-
tRNA[Sec] synthase (SepSecS) were associated with progressive
cerebellocerebral atrophy (PCCA), an autosomal-recessive pheno-
type of nondysmorphic profound mental retardation, severe
spasticity andmicroencephaly.23 These gene alterations abrogate
SepSecS activity and thus block the synthesis of tRNA[Ser]Sec,
and subsequent Se incorporation into selenoproteins.
In vivo studies have shown that Cys can replace Sec in the
Sec biosynthetic organisation, generating Cys-tRNA[Ser]Sec and
the subsequent insertion of Cys in some selenoproteins.24 This
is possible due to either substitution of Se2 by sulfide (S2) in
the SPS2 catalysed reaction; or substitution of SePO3
3 by
thiophosphates in the reaction with the O-phosphoseryl-
tRNA[Ser]Sec intermediate during Sec-tRNA synthesis. The
same study showed that the incorporation of Cys in selenopro-
teins is dependent of Se availability to the cells. Tobe et al.25
showed that some antibiotics could also interfere with Sec
insertion in murine EMT6 cells. Cells treated with doxycycline,
chloramphenicol and G418 caused lower Sec insertion in
thioredoxin reductase 1 (Trxr1), and GPx1 and 4. However,
Fig. 1 Selenoprotein synthesis pathway. Dietary Se intake, as either inorganic or organic species is metabolised to Se2, and the SeH3PO3, which is
incorporated into proteins via a unique tRNA pathway, where a seryl (Ser) residue is replaced with selenocysteine (Sec) prior to integration into
mammalian proteins. Deficiencies in key metabolic factors involved in selenoprotein synthesis have been associated with specific neurological disorders,
marked here in red. The inset in the dashed blue box is the simplified cloverleaf structure of mammalian tRNA[Sec] (adapted from Birringer et al.196),
showing variable (in blue) and modifiable (in red) bases. Abbreviations: C = pseudouridine; EFSec = Sec elongation factor; eIF4a3 = eukaryotic initiation
factor; i6A = N6-isopentenyladenosine; L30 = ribosomal protein L30; mcm5U = 5-methoxycarbonylmethyluridine; m1A = 1-methyladenosine;
mcm5Um = 5-methoxycarbonylmethyluridine-20-O-methylribose; SBP2 = Sec insertion sequence (SCIS) binding protein-2.
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Sec was also exchanged by arginine and tryptophan in addi-
tion to Cys. The specific mechanisms that are associated with
mis-insertion of amino acids in place of Sec and how they are
associated with changes in selenoproteins activity need to be
clarified, but these reports show another way selenoprotein
hierarchy is potentially regulated, which may also include
as-yet undetermined environmental factors.
Selenoprotein P and brain selenium
hierarchy
Selenoprotein expression is modulated by Se availability, and a
hierarchy is observed in response to dietary Se intake. In cases
of Se deficiency the synthesis of some proteins is maintained at
a higher level than that of others, suggesting that insuﬃcient
available Se results in competition between transcripts of
diﬀerent selenoproteins.26 Iodothyronine deiodinase 1 is atop
this hierarchy and is comparatively the least aﬀected by
restricted dietary Se; glutathione peroxidases GPx2 and GPx4
are less vulnerable to Se deficiency than GPx1 and GPx3; and
selenoprotein P (SelP) is in an intermediary position on this
selenoprotein transcription ladder.27
Some mechanisms underlying Se regulation of the seleno-
protein transcriptome have been identified. During Se defi-
ciency, non-essential selenoproteins are down regulated via
nonsense-mediated mRNA decay, which decodes the UGA-Sec
codon as a termination codon causing RNA degradation.28,29
Also, Se levels directly correlate with the degree of Um34 methyla-
tion (the single methyl group diﬀerentiating the two tRNA[Ser]Sec
isoforms30), one step of maturation of tRNA[Ser]Sec which can be
altered as a result of some mutations. The Um34-containing
isoform of tRNA[Ser]Se; 5-methoxycarbonylmethyl-20-O-methyl-
uridine (mcm5Um), is recruited for eﬃcient expression of the
stress-related selenoproteins; and the non-Um34-containing iso-
form, 5-methoxycarbonylmethyluridine (mcm5U), is not required
specifically. The distinct use of these tRNA[Ser]Sec isoforms shows
that this mechanism contributes to Se regulation for the purpose
of selenoprotein synthesis.28
The hypothesis that explains the hierarchy between seleno-
protein syntheses suggests that they are classified according to
their importance to the body. However, it is important to note
that Se concentration is highly variable within the periphery
(i.e. liver, kidneys, etc.), though in the brain Se levels remain
relatively stable by comparison during periods of deficiency.31
Additionally, the ability of organs outside the CNS to retain Se
is also variable. The CNS, together with reproductive and
endocrine organs, has the highest priority for Se both uptake
and retention during Se deficiency, although the Se concen-
tration in the CNS is low in comparison with other organs.32
Though interrelated, supply and retention are not exclusively
linked, and it is thus a testament to the importance of Se in
brain function that rigorous mechanisms to ensure adequate Se
levels are available in times of dietary shortage are in place. The
brain’s top position on a tissue-specific grading further indicates
that Se is essential for its normal metabolism.33 This is primarily
due to the high expression of apolipoprotein E receptor-2
(apoER2) at the blood–brain barrier (see below) to facilitate Se
uptake and strong SelP-apoER2 interaction within the CNS
providing an adequate pool of available Se. Selenium deficient
rats presented approximately 29% lower Se levels in the brain
compared to animals with a sufficient Se supply, which is not
nearly as dramatic as the 99% and 92% decrease in Se concen-
tration in the liver and kidneys of deficient animals.34 Se
distribution is heterogeneous among different brain regions,
and grey matter appears to have preference for greater uptake.
Imaging using a 75Se radiotracer combined with autoradio-
graphic localisation and proteomic analysis to profile Se levels
in different brain regions of rats fed a Se-replete diet revealed
that Se was enriched in choroid plexus, putamen, parietal
inferior lobule and occipital cortex.35 This observation has been
reflected in human brains, where the highest Se concentration
occurs in grey matter, with the putamen, parietal inferior lobule
and occipital cortex in particular, while the lowest levels are
found in the cerebellum and medulla.36
The mechanism that maintains Se levels in the brain at the
expense of other organs, even during times of deprivation, is
mainly orchestrated by SelP, which is recognised as the most
important Se supply to diﬀerent tissue types. The role of SelP to
deliver Se to cells is facilitated by the presence of ten SECIS
forms: one is situated in the larger N-terminal region, which
acts as an enzyme; and nine are located in a Sec-rich C-terminal
domain, providing a mechanism for transporting the highly
reactive Se atom safely, incorporated into the protein as Sec.37
Deletion of the conserved, non-SECIS containing 30UTR of SelP
does not aﬀect the eﬃciency of incorporation of multiple Sec
residues into SelP in vitro whilst still remaining sensitive to
ambient Se levels, indicating that the 30UTR are not involved in
Se incorporation per se.38 The structure of plasma SelP remains
unresolved, and there is some contention as to the number of
circulating isoforms of the protein. Ballihaut et al.39 recently
reported three isoforms in a human plasma standard reference
material, two of which incorporated Se, suggesting the third
was in fact a truncated variant.
Burk et al.40 recently proposed the mechanism by which Se
is delivered to the brain (represented in Fig. 2a). SelP from
plasma is endocytosed following docking with apoER2 at the
blood–brain barrier (BBB) in brain capillary endothelial cells
(BCECs) and choroid plexus epithelial cells, which facilitates Se
transport, in an as-yet unknown chemical form, into the brain.
Selenium is then delivered to brain cells via SelP synthesised by
astrocytes on the abluminal side of BCECs, composing both
the main transport mechanism and distinct pool of Se. Direct
transport of SelP to neurons from BCECs has not been
excluded. Neurons regulate Se levels via apoER2-mediated
uptake of SelP,41 which has obvious implications for AD due
its role in neurodevelopment and synaptic function. In the
periphery, apoER2 is widely expressed in the body and is also
involved in Se uptake in myoblasts42 and testis cells.43 In the
CNS, apoER2 is also expressed in choroid plexus and on PV
interneurons in the hippocampus, inferior colliculus, medial
septum, red nucleus, reticular thalamus and cerebellum.40,44
Critical Review Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Metallomics, 2015, 7, 1213--1228 | 1217
ApoER2 expression is regulated by physiological factors related
to developmental stage; fetal brain mRNA ApoER2 are more
than 9 times greater than that observed in adult brain, and
apparently not influenced by Se status.40 Although deletion of
apoER2 gene does not affect the whole-body Se levels, apoER2/
and SelP/ mice have lower Se levels in brain,45,46 and this
may be associated with uptake of Se during specific develop-
mental windows.40 In this study, fetal apoER2/ mice brains
contain 75% less Se levels compared to age-matched apoER2+/+
mice, decreasing to 39% when reaching adulthood. Moreover,
apoER2/ mice had no SelP in BCECs or choroid plexus cells at
the BBB, suggesting a key role of ApoER2 in brain Se uptake,
and also the presence of an unknown redundancy mechanism
for Se transport. It remains unclear if other members of the
lipoprotein receptor family may participate of SelP uptake,
since Burk et al.47 observed an alternative mechanism that
does not appear to depend directly on selenoproteins partici-
pating on the transfer of Se from pregnant dam to the fetus,
and it is unclear if this mechanism is conserved in the post-
natal period.
Though primarily expressed in astrocytes, neurons have also
been identified as a source of endogenous SelP48,49 in all the
Fig. 2 (a) SelP, the master protein driving Se bioavailability is synthesised in the liver from both inorganic and organoselenium compounds accessible
through dietary sources. At the blood–brain barrier, SelP releases Se into the CNS via the ApoER2 receptor, which is in turn incorporated into newly –
formed SelP in astrocytes (figure adapted from Burk et al.35), or is transported directly to neurons (dashed arrow). SelP is made available to neurons via the
same membrane-bound ApoER2, where additional selenoproteins essential to neurological function (blue box) are biosynthesised. (b) In cases of
deficient Se intake Um34 methylation is downregulated, causing premature termination of protein synthesis via failure of tRNA[Ser]Sec to decode the
UGA codon as Sec instead of a stop codon, and misincorpoartion of selenocysteine (Sec) as cysteine (Cys; in red). These three pathological features may
have downstream effects on a range of neurological disorders (red boxes).
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areas of the brain, though particularly high expression was
identified in the putamen and substantia nigra.50 In contrast to
apoER2/ animals, SelP/ mice present generalised Se defi-
ciency, and in brain this gene deletion causes severe neuro-
logical dysfunction.47,51 SelP/ mice showed decreased density
of PV interneurons in diﬀerent brain areas, most marked in the
inferior colliculus. This was associated with higher oxidative
damage and a behavioural phenotype, characterised by impair-
ments in contextual fear extinction, latent inhibition and
sensorimotor gating. These data suggest that besides the eﬀect
on PV-expressing neurons causing increased vulnerability to
oxidative damage, the behavioural deficits resulting from SelP
deletion are likely associated with impaired GABAergic function
of the inferior colliculus.44 Both SelP/ and apoER2/ mice,
when maintained on a Se-deficient diet, are more vulnerable to
neuronal damage and eventual neurodegeneration. In this way,
Burk et al.40 reported that extremely Se-deficient apoER2/ and
SelP/ mice displayed neurological dysfunction, while the
littermate wild type mice did not show equivalent disruption,
despite a decrease in brain Se levels. In another important
study,46 progressive neurodegeneration was evaluated in brains
of SelP/ postnatal mice maintained on a Se-deficient diet
after weaning. Higher lipid peroxidation and decreased dendrite
length and spine density was observed, and the areas more
susceptible to neurodegeneration during this post-weaning devel-
opmental window were the forebrain bundle, somatosensory
cortex and lateral striatum. In the hippocampus decreased dendrite
length and spine density was also present, which might be
associated with the disrupted hippocampal-dependent learning
and alteration to synaptic transmission observed in these mice.
As Scly is essential for breakdown of Sec into L-analine and
Se2, it has been proposed that this enzyme plays important
role in Se metabolism in diﬀerent tissue, and interacts with
SelP to maintain adequate selenoprotein function in the brain.
Although Scly/ mice do not demonstrate neurological dys-
function,51 deletion of both Scly and SelP exacerbates the
neurological phenotype of SelP/ mice, which display
impaired motor coordination and locomotion compared with
SelP null mice alone. Moreover, Scly/SelP/ mice have lower
expression of Trxr1, GPx1 and selenoprotein M (SelM) than
SelP/ mice, showing that interplay of Scly and SelP helps
maintain selenoprotein levels within the brain.52
Selenium and other selenoproteins:
role in brain function
Selenium appears to have a multifaceted role in the nervous
system, with a number of studies showing its importance to
normal brain physiological function. The antioxidant activity of
selenoproteins in the CNS is well established, and lower levels
of Se has been associated with brain injury.53 Selenium treat-
ment as organic selenomethionine and inorganic SeO3
2
resulted in a similar increased activity of antioxidant enzymes,
scavenging of reactive oxygen species (ROS) and reduced pro-
tein carbonyl content of patulin-induced brain damaged rats,54
and reduced the pro-oxidant eﬀects of glyceryl trinitrate in a
rat model of migraine headaches.55 Administration of SeO3
2
to suckling pups whose dams had methimazole-induced
hypothyroidism decreased total oxidant status and reduced
degenerative changes in the granular cell layer of the dental
gyrus,56 and increased levels of brain-derived neurothophic
factor (BDNF) in the hippocampus and cerebellum of both
hypothyroid and control groups.57 In a rat model of postnatal
protein malnutrition oral Se and zinc (Zn) supplementation
increased not only antioxidant enzyme activity, but also corrected
the neurobehavioral deficits caused by a protein-deficient diet.58
Besides the role of Se as essential component of the anti-
oxidant system in the brain, studies have also shown that Se
can act in response to oxidative stress through regulation
of Ca2+ channels and mitochondrial biogenesis. Mice dorsal
ganglion root cells treated with Se showed reduced Ca2+ release
induced by H2O2 when compared with non-treated cells, with
corresponding decreases in apoptosis and lipid peroxidation
levels, and increased levels of GPx and glutathione (GSH)
activity.59 In a traumatic brain injury animal model exhibiting
oxidative stress, increased apoptosis and activation of transient
receptor potential vanilloid 1 (TRVP1) cation channels, Se
treatment modulated Ca2+ entry through TRVP1 in neurons,
reduced levels of ROS, prevented apoptosis, and reduced activity
of caspases 3 and 9. Since brain injury induces Ca2+ influx and
mitochondrial dysfunction in neurons, these data show that Se
can increase cell viability not only as an antioxidant, but also by
modulating apoptotoic pathways and mitochondrial function.60
Studies with murine hippocampal HT22 cells treated with
SeO3
2 clearly showed improved mitochondrial function, even
after glutamate exposure and hypoxia. This was associated with
activation of complexes I, II + III and IV, and increased
mitochondrial respiratory rate. Selenium administration
increased levels of peroxisome proliferator-activated receptor
g-coactivator-1a (PGC-1a) and nuclear respiratory factor 1
(NRF1), two important nuclear transcriptional factors asso-
ciated with mitochondrial biogenesis. This role of Se appears
to be mediated through activation of the cyclic adenosine
monophosphate response element-binding protein (CREB)
and activated protein kinase (AKT) cycles.61–63
Synthetic organoselenium compounds have been studied as
potential antioxidant therapies due their lower toxicity com-
pared to inorganic forms of Se. Diphenyl diselenide [(PhSe)2]
mimics GPx activity, producing both beneficial or harmful
eﬀects, depending on dose and route of administration.64 Acute
treatment of rat hippocampal slices with (PhSe)2 modified
various proteins involved in glutamate signaling damage to
astrocytes.65 Conversely, (PhSe)2 demonstrated a neuroprotective
activity in animal models of autoimmune encephalomyelitis and
hypothyroidism due its antioxidant and anti-inflammatory
role.66,67 A derivate of (PhSe)2, m-trifluoromethyl (m-CF3-PhSe)2
and the Se-containing salicylic acid derivative 5–50-diselanediylbis-
(2-hydroxybenzoic acid) both exhibit antinociceptive action by
interaction with serotoninergic system, as well as an anti-
inflammatory role in mice.68,69 Selenium supplementation as
a promoter of antioxidant activity does appear to be somewhat
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dependent on the chemical form; 3-methyl-1-pheny-2-(phenyl-
seleno)oct-2-en-1-one was less effective as an antioxidant com-
pared to SeO4
2, though it did reduce adenosine deaminase
activity, suggesting a potential immunomodulatory property.54
Musik et al.70 examined two other Se-containing molecules;
(4-(o-tolyl-)-selenosemicarbazide of 2-chlorobenzoic acid; 3-(2-
chlorobenzoylamino-)-2-(o-tolylimino-)-4-methyl-4-selenazoline)
reporting differential impacts on brain antioxidant mechanisms,
including GPx and superoxide dismutase-1 (SOD-1). These con-
tradictory results regarding Se supplementation on brain function
are likely due to the variety of chemical structures, dose, route of
administration and the animal models used. More targeted
studies regarding the role and the safety of these compounds
are required before they can be considered as potential anti-
oxidant therapeutics in humans.
The apparent neuroprotective role of Se supplementation in
the brain is not only directly associated with antioxidant eﬀects
of organic and inorganic Se species, but also suggests a role in
de novo selenoprotein synthesis, as demonstrated by increased
activity of certain selenoproteins following Se treatment (Fig. 2).
Methamphetamine treatment decreased levels of GPx1 and
GPx4 in SH-SY5Y cells; an eﬀect that was arrested with addition
of SeO3
2 24 hours after methamphetamine exposure.71 In
their patulin-induced brain damaged rats, Song et al.72 showed
that, although both SeO3
2 and selenomethionine were able to
oﬀer some degree of increased antioxidant activity, the organic
form of Se was more eﬃcient in increasing the expression and
activity of TrxR, GPx1 and GPx4.
The GPx family of enzymes are expressed in both neurons
and glia,73,74 and are recognised as one of the most important
mechanisms protecting against ROS-induced damage.75 Among
these isoenzymes, GPx4 protects cells against lipid hydroperoxide
damage76 and is the most expressed GPx in brain, found in
neurons of cerebellum, hippocampus and hypothalamus.77
Following brain injury, GPx4 is also observed in reactive astro-
cytes, suggesting that this GPx may have an important role in
the protective cellular response to stress-induced oxidative
damage and apoptosis.78 Autooxidation of dopamine to the
reactive dopamine quinone causes a decrease in GPx4 activity
by covalently modifying this mitochondrial enzyme,79 suggest-
ing that antioxidant properties of GPx4 are restricted by dopa-
mine breakdown in neurons. Wirth et al.20 showed that mice
with a neuron-specific deletion of GPx4 had mild neurological
dysfunction, and that GPx4 deficiency may contribute to dys-
function in other selenoproteins expressed in the brain, including
TrxR, SelM and selenoprotein W (SelW).
TrxR is abundant throughout the CNS. In the mouse brain
TrxR1 (the cytosolic isoform) is abundantly expressed in glial
cells of the cerebellar white matter and TrxR2 (the mitochon-
drial isoform) is observed mainly in the cell bodies of neurons
localised in the Purkinje and molecular cell layers in the
cerebellum.80 This selenoenzyme plays an important role in
maintaining the redox balance inside cells. It forms, together
with thioredoxin (Trx), a disulfide reductase system.81 Mitozo
et al.75 showed that TrxR inhibition resulted in increased DNA
damage and poor cell viability following a H2O2 challenge in
neuronal C6 cells, though it did not impede the ability of N2a
cells to dispose of peroxides. However, specific inhibitors used
to estimates the relative role of the Trx2, glutathione system
and catalase for hydrogen peroxide detoxification in diﬀerent
preparations from rat brain showed that Trx2-system contri-
butes to over 60% of the intra-mitochondrial H2O2 turnover,
whereas the glutathione system contributes only about 20%
to H2O2 detoxification reactions in the rat hippocampus.
82
Recently, Cohen-Kutner et al.,83 using two thioredoxin mimetic
peptides (NAc-Cys-Pro Cys-amide; CB3 and Ac-Cys-Gly-Pro-Cys-
amide; CB4) as a treatment for oxidative stress in SH-SY5Y
human neuroblastoma cells, observed anti-inflammatory and
antioxidant eﬀects of both peptides, as well as reduced apop-
tosis markers. The potentially protective role of TrxR is also
important for dopaminergic cells, which exhibit high levels of
oxidative stress when undergoing parkinsonian degeneration.
In cells exposed to 6-hydroxydopamine (6-OHDA) and paraquat,
inhibition of TrxR potentiated mitochondrial dysfunction,
decreased maximal and reserve respiratory capacity, and
increased H2O2 levels and cell death through oxidative stress.
Also, TrxR2 deficient cells showed decreased basal mitochon-
drial oxygen consumption rates.84 Immunoreactivity of TrxR2
was increased in the spinal neurons and hippocampus of aged
dogs, suggesting that this selenoenzyme is important for main-
taining neuronal homeostasis following the increase in oxidative
stress experienced during normal ageing.85 Human astrocytomas,
which are the most common form of gliomas, were found to
express TrxR in a manner that correlated with both tumour
grading and Ki-67 labelling index (a marker of cell proliferation),
with both quantitative reverse transcription polymerase chain
reaction and immunostaining confirming higher TrxR levels
correspond to tumour severity.86 Though no clear causative link
between TrxR activity and astrocytoma proliferation has been
identified, this association with cancer progression and TrxR
expression is a tantalising research direction considering that,
besides its antioxidant role, the TrxR class of enzymes contributes
to several physiological and biochemical functions, including cell
growth, maintenance and programmed death.
Most selenoproteins have the conserved Cys-X-X-Sec (or CXXU)
redox motif, including selenoproteins H, W, T and O. Other
selenoproteins include Cys-X-X-Cys (CXXC) in TxrRs, Cys-X-Sec
(CXU) in selenoprotein-15,87 Sec-X-X-Cys (UXXC) in SelP,88 as well
as Sec-X-X-Ser (UXXS) and Sec-X-X-Thr (UXXT), identified in a
range of prokaryotic selenoproteins withmammalian homologs.89
Their role it is not well elucidated, though it is thought they act as
thiol–disulfide oxidoreductases that participate in the formation
of disulfide bonds.37,90–94 SelM has an endoplasmatic reticulum
(ER)/Golgi-directing signaling peptide with a short N-terminal
extension, the CXXU motif, and a thioredoxin-like domain in
the middle.95 It is characterised by a two-layer a/b/a sandwich
with a babbba secondary structure pattern, and an ER retention
signal tetrapeptide in the C-terminal.96,97 In the mouse brain,
SelM expression is highest in the olfactory bulb and cerebellum,
with intermediate levels found in the hypothalamus and brain
stem and low expression in the hippocampus and cerebral
cortex.98 The precise role of SelM is not well understood; some
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studies using mice overexpressing this protein have shown that it
promotes antioxidant activity in brain, in this case increasing the
activity of other antioxidant enzymes including SOD-1 and GPx,
which could be enhanced with further dietary supplementation of
Se.99–102 SelM knockdown primary cortical neurons show dis-
turbed Ca2+ homeostasis compared to controls.99 Pitts et al.98
observed that the deletion of SelM gene in mice did not result in
morphological changes to the brain, nor did it result in motor or
cognitive deficits and anxiety-like behavior. However, these mice
presented an obesity phenotype accompanied by higher leptin
levels and elevated hypothalamic leptin resistance when com-
pared with wild type controls. As SelM is expressed in high
quantities in the hypothalamus, the authors hypothesised that
deletion of this gene adversely affected hypothalamic thyrodoxin
balance and cause metabolic dysfunction, indicating that SelM
plays an important role in maintaining redox balance in brain
areas associated with high metabolic output, though further
investigation is obviously required to confirm this supposition.
Yim et al.100 showed that the association between SelM
overexpression and Se treatment via intraperitoneal injection
contributed to the activation of ERK MAPK signaling pathway,
an important mechanism involved in the modulation of protein
phosphorylation. Additionally, hippocampal mouse cells and
C8-D1A cerebellar cells overexpressing SelM exhibited decreased
cytosolic Ca2+ in response to oxidative stress, without aﬀecting
basal Ca2+ levels, suggesting that SelM canmodulate the apoptotic
pathway by mediating Ca2+ release from internal cell stores.99
Another proposed mechanism for the role of SelM in providing
neuroprotection was the observation that SelM interacts with
galectin-1,103 a b-galactoside-binding lectin associated with modu-
lation of microglia activation in neuroinflammation, neuronal
myelination and neuronal stem cell proliferation.104,105 Addition-
ally, it was recently shown that overexpression of SelM could
change the expression of other proteins; Kim et al.102 showed that,
when compared with wild type controls, mice overexpressing SelM
upregulated expression of several diﬀerent genes, including
creatine-kinase B-type and LDH-B, essential for energy homeo-
stasis; the E3 ubiquitin-protein ligase RING1 that participates in
cellular defense against environmental insult; eIF-4H, which
facilitates the binding of initiator rRNA to ribosomes, regulating
protein synthesis; and SytXV, that regulates Ca2+-dependent
membrane traﬃcking, and thus is crucial for maintenance of
adequate neurotransmitter release. On the other hand, these mice
demonstrated downregulation of CENP-N, which mediates mito-
tic progression, assembly of kinetochore proteins and chromo-
some segregation; dihydropyrimidinase-related protein 2, that
plays important role in neurite guidance; and proteasome subunit
K. This study strongly suggests that the protective role of SelM
may in fact be carried out indirectly through the modulation of
diﬀerent genes that regulate cell viability.
SelW is abundant in brain of chickens,106,107 and is highly
stable in rat brain even during Se-deficiency. In vivo, where Se
supply is entirely dictated by the media in which cells are
grown, SelW expression is highly dependent on ambient Se
concentrations. Low levels (109 mol L1) of Se yielded the
highest levels of SelW mRNA expression, which progressively
increased over time, along with better general embryonic chicken
neuronal health. High levels of Se (up to 105 mol L1) were
obviously neurotoxic, with SelW mRNA expression suppressed.108
This clearly indicates that neurons depend on an external Se pool
to which it can draw from, and has a place lower on the Se brain
hierarchy. It is more likely that delivery of Se from astrocytes
as SelP to endogenous neuronal apoE2 receptors is the more
controlledmechanism of neuronal Se uptake, as opposed to direct
translocation of SelP immediately following BBB transit. This
study, though clearly useful in investigating what, if any, buﬀering
capacity neurons have for excessive Se, does however highlight a
very pertinent point when considering in vitro studies of Se (or any
other low-level essential element) metabolism: what conclusions
can appropriately be drawn when the multicellular interplay that
typically regulates Se hierarchy are removed and the system is
viewed in isolation? As such, these studies should be also
considered somewhat in vacuo; in this case purely as an
example of how excessive Se levels impact upon SelW expres-
sion and neurotoxicity.
In murine brain tissue, SelW is expressed in axons and
dendrites of neurons in several nuclei, mainly the cortex, hippo-
campus and cerebellum. It is highly abundant in apical dendrites
of most pyramidal neurons in the hippocampus, cingulate cortex
and piriform cortex, and is also expressed in synapses.51,109,110
However, as observed for other selenoproteins, SelW expression is
dependent on the master regulator SelP, as SelP deleted mice
present a reduced level of SelW mRNA.110 SelW is present in
survival motor neuron protein (SMN) complexes, the major
components of the spliceosome (the machinery that carries out
pre-mRNA splicing).111 This particularly interesting study showed
that SelW is in part dependent of SMN-complexes due to its
neuronal transport along neurites, since SelW was decreased by
17% in neurites of SMN-depleted NSC-34 cells. The role of SelW in
the brain remains unclear: its redox motif suggests that this
selenoprotein acts as antioxidant in diﬀerent cells, though in
muscle cell cultures depletion of SelW was compensated for by
alternate antioxidant proteins, suggesting its major function is
not antioxidant activity alone.112 Also, because SelW is highly
expressed in brain areas associated with synaptic plasticity,
Raman et al.110 suggested that it is essential for maintaining
redox homeostasis and mediates proper synaptic adaptation and
development.
Several selenoproteins are not highly expressed in brain,
such as selenoproteins S (SelS) and H (SelH), though recent
studies are attempting to determine their role in CNS, suggesting
that whilst they exist in low abundance, they may be essential
participants in normal brain function. Speciation of seleno-
proteins is analytically challenging, and in situ hybridisation
often lacks the necessary sensitivity to probe selenoprotein RNA
where expression is very low. Selenoprotein S appears to have a
neuroprotective eﬀect, and is foundmainly in neurons, sparingly
in astrocytes; and animal studies have reported that it is typically
confined to the hippocampus and cortex.113–115 SelS expression
is induced in reactive astrocytes as part of an activation program
triggered by astrogliosis-inducing stimuli.114 As a result, SelS
overexpression decreased ER-stress and IL-6 release in astrocytes.
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These results were confirmed by Liu et al.,115 who observed
increased SelS expression after 3–7 days of ischemic reperfusion,
suggesting that SelS modulates astrocyte function by reducing the
synthesis and release of inflammatory cytokines and limiting
degradation of unfolded proteins. Considering that previous stu-
dies have shown that SelS has an important anti-inflammatory role
in different tissue types,116,117 other work regarding the role and
therapeutic potential of this selenoprotein in brain are encour-
aged. In the same way, although SelH is only moderately expressed
in the brain,118 overexpression in neuronal cells improved mito-
chondrial biogenesis and functional performance. Overexpression
of SelH in HT-22 neurons increased the respiratory function of
mitochondria and preserved UVB stress-induced mitochondrial
membrane potential depolarisation. The study of neurons either
overexpressing SelH or with the gene ablated revealed that this
selenoprotein improved mitochondrial biogenesis signaling via
PGC-1a, NRF1 and mitochondrial transcription factor A (Tfam),
likely mediated by modulation of CREB dependent PGC-1a activa-
tion.61,62 The protective role of SelH is also possibly linked to its
capacity to maintain genomic stability, protecting the cells against
replicative senescence under chronic oxidative stress.119 According
to this hypothesis, besides its direct antioxidant role arising from
the presence of the CXXU motif, which prevents ribosomal DNA
oxidation in the nucleoli, SelH may induce de novo synthesis of
GSH and phase II detoxification enzymes. Although this theory
was not evaluated in brain cells, it does pose one possibly
important role of this selenoprotein in neurodegenerative diseases
associated with ageing. The examples described here exemplify the
ways by which selenoproteins can exert a neuroprotective role,
even though they are expressed at relatively low levels.
Selenium in brain diseases
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative condition charac-
terised by progressive loss of memory and cognition, and com-
promising of daily activities. Its key pathological features are
neuron death, loss of synaptic connections, extracellular deposi-
tion of beta-amyloid (Ab) protein aggregates (plaques), and intra-
cellular precipitation of hyperphosphorylated tau protein, which
manifest as neurofibrillary tangles.120–122 Oxidative stress is a
central component of AD pathogenesis, with ROS adversely
affecting mitochondrial function, synaptic transmission, axonal
transport, and stimulating neuroinflammation.123–125
Studies in humans have reported negative correlations between
cognitive decline and Se levels.126 Selenium status in the elderly
with mild cognitive impairment (MCI) and AD compared to
healthy cognitively intact controls revealed a decrease in the Se
content of erythrocytes that correlated with a decrease in cognitive
function. However, plasma Se was not significantly diﬀerent
between healthy and MCI participants.127 As plasma is a marker
of recent exposure and erythrocytes tend to report longer-term Se
status, these data suggest that chronic deficiency correlates with
cognition decline. Gonza´lez-Domı´nguez et al.128 reported lower Se
levels in serum from AD patients in comparison to MCI elderly,
although both groups were not considered deficient. Even in
‘‘mild’’ AD patients (defined as a Mini-Mental State Examination
[MMSE] scoreZ20) Se levels in plasma were reported to be lower
compared to healthy age-matched elderly subjects.129 These data
are in agreement with previous studies that suggest that a lack of
Se might increase the risk of dementia.127,130 Supplementation
with compounds containing Se has shown potential for stimulat-
ing cognitive improvement, although this eﬀect cannot be directly
attributed to Se alone.131,132 Cardoso et al.133 showed that the daily
intake of one Brazil nut over 6 months, which provides about
288 mg of Se, was associated with cognitive performance improve-
ment assessed by constructional praxis and animal naming; both
subtests of the CERAD battery. These data are promising; though
as Brazil nuts contain other antioxidant components, more studies
are required to elucidate the precise eﬀects of selenium intake on
cognition via this dietary source.
Animal models and in vitro studies have also provided some
insight into the role of Se on AD pathogenesis. A Se deficient
diet was associated with increased Ab plaque formation in the
brains of Tg2576 transgenic mice.134 Sodium selenate treat-
ment reduced tau phosphorylation in both cell culture and tau
transgenic animal models. In cells, the treatment antagonised
the protein phosphatase 2A inhibitor OA,135 activated the
protein phosphatase 2A and dephosphorylated tau.136 This
treatment prevented and reversed memory and motor deficits;
neurofibrillary tangles formation and neurodegeneration in
transgenic animals with tau dysfunction. Although SeO3
2
appears to be more toxic to cells, the treatment with this
inorganic Se compound to streptozotocin toxin model of mental
impairment improved tolerance to oxidative stress and pre-
vented cognitive decline.137 In hippocampal and cortical cells,
it was associated with lower activity of a- and b-secretases and
corresponding reduced production of Ab1–40 and Ab1–42.
138
Treatment of triple-transgenic AD mice expressing mutant
forms of human APPswe, PS1M146V, and tauP301L with seleno-
methionine resulted in reduced total and phosphorylated tau,
lower inflammatory biomarkers and improvement in cogni-
tion.139 Organoselenium compounds also display interesting
effects in improving AD pathology in murine models: p, p0-
methoxyl-diphenyl diselenide treatment to streptozotocin-
exposed mice slowed memory decline, reduced oxidative stress
and normalised acetyl-cholinesterase activity.140 Selenium-
containing 8-hydroxyquinoline derivates bound to Cu2+, Fe2+
and Zn2+ inhibited aggregation and disassembled Cu2+-induced
aggregates of Ab.141
Some studies have shown an association between certain
selenoproteins and pathological features of AD. In the post-
mortem brain SelP was found to colocalise with senile plaques
and neurofibrillary tangles,142 and was elevated in the choroid
plexus and cerebrospinal fluid of AD patients.143 Considering
that oxidative stress is a hallmark of AD, these data could
suggest that SelP might act by protecting neurons against the
hallmark lesions damage of the disease via its prominent
antioxidant role, or by transporting Se to the synthesis of other
antioxidant selenoproteins. SelP encodes two His-rich regions
that act as high-aﬃnity binding sites for transition metals,
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potentially blocking metal-mediated Ab1–42 aggregation and
subsequent ROS generation.144,145 This protein also appears
to modulate tau aggregation, with Du et al.146 showing that the
His-rich domain of SelP inhibited aggregation and dis-
assembled formed aggregates of tau induced by the presence
of Cu+/Cu2+. These two His-rich regions associate with the
acidic tail of a-tubulin via a charge–charge interaction. This
suggests that SelP possibly participates in microtubule events,
which are associated with maintenance of cell polarity, intra-
cellular transport and cell division and migration, although the
exact role of SelP within microtubules has yet to be elucidated.147
Overexpression of SelM, as well as Se treatment contributes
to activation of ERK signalling, which induces a decrease in
tau phosphorylation, a-secretase and g-secretase activity and
an increase in b-secretase.100 Selenium treatment to SelM-
overexpressing mice resulted in significant ROS inhibition,
reduced mitochondrial damage, Ab aggregation;101 and increased
g-secretase activity.102
Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disorder charac-
terised by loss of pigmented dopaminergic neurons in the
substantia nigra (SN) pars compacta together with the presence
of intraneuronal proteinacious inclusions of a-synculein termed
Lewy bodies. Several mechanisms have been proposed that
induce toxicity inside the cytoplasm of neurons and also in the
extracellular space, including a-synuclein/neuromelanin
pathology,148 ceruloplasmin dysfunction,149 copper and cupro-
protein dyshomeostasis11 and an iron/dopamine-mediated oxi-
dative stress cycle.150 Dopaminergic neurons are particularly
vulnerable to oxidative damage, potentially due to their propen-
sity to accumulate iron with age,151,152 and thus oxidative stress
presents a central role on PD pathogenesis,153–155 and a logical
target of selenoprotein antioxidant activity.
An association between Se status and PD pathology is not
clear. Shahar et al.156 measured plasma levels in 1,012 elderly
(Z65 years of age) Italian subjects and were able to associate
performance-based assessments of coordination with circulating
Se concentrations. Although there was no measurable associa-
tion between plasma Se and PD, older subjects demonstrated
a significant association between circulating Se levels and
decreased performance in neurological coordination tests.
In other smaller PD cohorts (o100 PD subjects) no diﬀerence
in plasma Se levels compared to healthy controls have been
identified.157,158
As noted by Shahar et al.,156 causal influence between Se and
PD pathology is diﬃcult to ascertain, particularly considering
motor function is often related to malnutrition, and thereby
circulating Se levels. Dietary Se may indeed be such a con-
founding factor that any possible causal, or even indicative
relationship between circulating Se and PD (or any other
chronic illness, for that matter) impossible to elucidate. Sele-
nium in primary food sources is heavily dependent on the Se
content of soil, which is highly variable around the world; soil
Se levels in parts of Scandinavia, New Zealand and a wide belt
of land extending from Siberia through north-eastern China are
notably low, and are particularly replete in the US Midwest and
Amazon regions of the Americas.159 In contrast to Shahar’s
comments that PD pathology may cause malnutrition and Se
deficiency, a large cohort of PD patients and controls from
eastern China, (238 PD; 302 controls) reported that plasma Se
(and iron) levels were significantly increased in patients with
idiopathic PD.160 Clearly, epidemiological studies with a higher
statistical power are required to confirm or deny a possible
association between circulating Se and PD. Additionally, it is
advisable that several diﬀerent biological matrices (e.g. erythro-
cytes, hair, nails etc.) should be used to evaluate Se levels. This
would provide a more comprehensive overview of Se levels, and
could potentially be used to identify times of exposure. Further,
speciation of selenoproteins, as opposed to measuring total Se
levels provides another avenue to identify specific Se function-
ality and its possible role in disease process.
Several studied have suggested a Se-deficient diet may con-
tribute to dopaminergic cell vulnerability,161,162 particularly
prior to exposure to parkinsonian neurotoxins.163 Conversely,
Se pretreatment somewhat mitigated 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced depletion of striatal dopa-
mine in a dose dependent manner, though only a high dose of
3 mg kg1 of Se (as SeO3
2) produced a statistically significant
eﬀect.164 In a paraquat animal model of PD when treated with
SeO3
2 at a low dose (in drinking water at 11.8 mg L1) presented
normalisation of motor activity when co-administered with the
toxin.165
SelP is localised within cell bodies, axons and presynaptic
terminals of SN neurons, and in PD patients this selenoprotein
co-localises within Lewy bodies.50 Like SelP, GPx4 is also
reduced in the SN of the PD brain, but is increased relative to
cell density in surviving neurons.166 Hauser et al.79 showed that
GPx4 is covalently modified by dopamine quinone, an oxidised
and reactive metabolite of dopamine, and that this deleterious
product of neurotransmitter breakdown may result in degrada-
tion and reduced activity of this antioxidant selenoprotein. More
studies are necessary to elucidate the precise mechanisms by
which GPx metabolism is altered during PD progression.
Other neurodegenerative diseases
A number of other progressive neurological disorders have been
studied with regard to a possible association with Se metabolism
and selenoprotein activity. Multiple sclerosis (MS) is one such
chronic, progressive, inflammatory disease aﬀecting the CNS
with a possible link to Se. Although the aetiology of MS remains
elusive, it is believed that disease onset and development depend
on a genetic and environmental interaction. The pathogenesis of
this disease is characterised by abnormal immune response
against self-antigens, resulting in inflammation and massive
neurodegeneration characterised by marked demyelination.
Additionally, infiltration of pro-inflammatory and autoreactive
leukocytes into the brain initiates a cascade of events including
blood–brain-barrier disruption, microglial activation and excito-
toxicity; all potentiating oligodendrocyte death and axon
damage.167–169 There is growing evidence that the involvement
of oxidative stress in MS pathogenesis as a crucial factor in
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initiating and perpetuating mechanisms involved in neuro-
degeneration. Glutathione peroxidase activity, as well other
antioxidant enzymes, is decreased in MS patients when com-
pared to the control subjects.170,171 In a proteomic study,
among a set of 44 proteins that discriminated experimental
autoimmune encephalomyelitis (EAE) rats from control groups,
GPx3 was increased in EAE animals.172 Selenium levels tend to
decrease in MS, as observed in a cohorts of Iranian173 and
Polish patients.174 Complementing the suggestive data regarding
a role of Se in MS pathogenesis, Chanaday et al.66 observed that
treatment with diphenyl diselenide to the EAE animal model
reduced signs of the disease phenotype, partly by preventing the
reduction in body weight that accompanies the disease progres-
sion and decreased the time and the severity of symptoms. In
these animals, the treatment also improved immune system
function by diminishing the extent of infiltrating macrophages
and controlling mononuclear cell proliferation.
Amyotrophic lateral sclerosis (ALS) is another degenerative
disease, in this case characterised by motor neuron loss in the
brain and spinal cord, which leads to muscle atrophy, weakness
and fasciculation.175 Although the cause of ALS is unknown,
several studies indicate a link between genetic and environ-
mental factors, including excessive exposure to inorganic Se.
This association was first suggested in 1977, when researchers
observed a higher prevalence of ALS in a known seleniferous
area.176 In a northern Italian locale, where some inhabitants
consumed drinking water with unusually high inorganic Se
content, a higher risk of ALS was observed, with dose–response
relation.177,178 ALS patients presented higher SeO3
2 levels and
lower organoselenium compounds, particularly SelP, in CSF
compared with healthy control subjects.179 This finding is
something of a curiosity, as SeO3
2 is not typically found at
high levels in biological fluids; conversion to non-redox active
forms occurs rapidly through a reaction with GSH, as SeO3
2 is
toxic,180 though improved analytical technology has identified
the presence of SeO3
2 at low ng mL1 concentrations in urine181
and serum.182 It should be noted that the same method used in
this study previously failed to identify SeO3
2 in CSF samples.183
Selenite is, however, toxic, though paradoxically it has been shown
to offer some degree of neuroprotection against lead neurotoxicity
in Caenorhabditis elegans,184 though this may result from conver-
sion to other selenoproteins rather than activity of the SeO3
2
itself. Selenium in excess has neurotoxic effects to motor neuronal
cells in vitro. Human neuroblastoma SKNBE cells were more
vulnerable to Se toxicity when compared with kidney and prostatic
cells when treated with organic and inorganic Se, even at a low
dose (0.1 mM).185 Selenite induced degeneration of cholinergic
and GABAergic neurons and impaired locomotor activity in
Caenorhabditis elegans.186–188 The elevated SeO3
2 in CSF of ALS
patients may be due to excessive exposure to this compound from
environmental sources, alteration of the body’s detoxification
capacity or even genetic modifications.
Huntington’s disease (HD) is an autosomal dominant neuro-
degenerative disease caused by increased repetition of CAG
trinucleotide in exon 1 of the Huntington gene, resulting
in polyQ-expanded sequence in N-terminal region of the
Huntington protein. This genetic alteration makes the Huntington
protein more prone to aggregation, which compromises protea-
somal activity, impairs mitochondrial function, increases oxidative
stress and contributes to neurodegeneration.189–191 Clinically, HD
is characterised by chorea, psychiatric disturbance and cognitive
decline.192,193 Although Se levels in plasma were not different
between HD patients and healthy controls, HD patients presented
a decrease in regional brain Se content; specifically in the putamen,
dorso-lateral prefrontal cortex, primary visual cortex, cingulate
gyrus and cerebellum.194 Treatment of N171-82Q HD mice with
SeO3
2 significantly protected against decreased brain weight
and reduced Huntington protein aggregation and oxidised
glutathione.194 In another HD mice model (3-nitropropionic
acid exposure) treatment with ((Z)-2,3-bis(4-chlorophenyl-
selanyl)prop-2-en-1-ol)(bis selenide) improved locomotor activity
and motor coordination, restored succinate dehydrogenase
enzyme activity and protected against oxidative stress.195
Although there are few studies investigating Se in HD, these
findings suggest that Se may be a potential avenue of explora-
tion with regard to prevention and treatment of HD, and more
studies are therefore encouraged.
Conclusions
Selenium has an essential role in the brain; not only due to its
direct antioxidant role, but also via its participation in main-
taining redox balance, mitochondrial dynamics, regulation of
Ca2+ channels and modulation of neurogenesis. The relevance of
Se in the pathogenesis of diﬀerent neurological diseases has
been shown by several studies in humans, animal models and
cell culture that all associate Se deficiency with a disturbance in
brain metabolism. It is important to note that the strong
hierarchical nature of Se regulation in the brain, and its ability
to remain somewhat eﬃciently isolated from Se deficiency in the
periphery, and thereby in vitro studies that control ambient Se
levels in a manner not reflective of in vivo Se metabolism are
suited only to investing a specific selenoprotein in isolation, as
opposed to the interplay between the 30+ known selenoproteins
in toto. Future research is required to fully elucidate the role
of diﬀerent selenoproteins in brain cells, and in turn this will
provide potential uses of selenoproteins as biomarkers of normal
or pathogenic biological processes in CNS. As recognition of the
importance Se has in maintaining normal brain function, studies
examining the benefits of Se supplementation are emerging, but
literature is still unclear regarding the precise eﬀects of diﬀerent
forms and doses of Se. Thus, additional experiments investigating
the potential neurotoxicity of Se overload are also required to
better assess the safe range of Se exposures.
Notes and references
1 K. Schwarz and C. M. Foltz, J. Am. Chem. Soc., 1957,
79, 3292.
2 L. Flohe, W. Gu¨nzler and H. Schock, FEBS Lett., 1973, 32,
132–134.
Metallomics Critical Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1224 | Metallomics, 2015, 7, 1213--1228 This journal is©The Royal Society of Chemistry 2015
3 G. V. Kryukov, S. Castellano, S. V. Novoselov, A. V. Lobanov,
O. Zehtab, R. Guigo´ and V. N. Gladyshev, Science, 2003,
300, 1439–1443.
4 M. Roman, P. Jitaru and C. Barbante, Metallomics, 2014, 6,
25–54.
5 J. Gromadzin´ska, E. Reszka, K. Bruzelius, W. Wsowicz and
B. Åkesson, Eur. J. Nutr., 2008, 47, 29–50.
6 D. H. Holben and A. M. Smith, J. Am. Diet. Assoc., 1999, 99,
836–843.
7 M. Be´langer, I. Allaman and P. J. Magistretti, Cell Metab.,
2011, 14, 724–738.
8 X. Wang and E. K. Michaelis, Front. Aging Neurosci., 2010,
2, 12.
9 A. Federico, E. Cardaioli, P. Da Pozzo, P. Formichi,
G. N. Gallus and E. Radi, J. Neurol. Sci., 2012, 322, 254–262.
10 W. R. Markesbery, Free Radical Biol. Med., 1997, 23, 134–147.
11 K. M. Davies, S. Bohic, A. Carmona, R. Ortega, V. Cottam,
D. J. Hare, J. P. M. Finberg, S. Reyes, G. M. Halliday,
J. F. B. Mercer and K. L. Double, Neurobiol. Aging, 2014,
35, 858–866.
12 M. Navarro-Alarcon and C. Cabrera-Vique, Sci. Total
Environ., 2008, 400, 115–141.
13 A. A. Turanov, A. V. Lobanov, D. L. Hatfield and V. N.
Gladyshev, Nucleic Acids Res., 2013, 41, 6952–6959.
14 V. M. Labunskyy, D. L. Hatfield and V. N. Gladyshev,
Physiol. Rev., 2014, 94, 739–777.
15 J. N. Gonzalez-Flores, N. Gupta, L. W. DeMong and P. R.
Copeland, J. Biol. Chem., 2012, 287, 38936–38945.
16 A. L. Bifano, T. Atassi, T. Ferrara and D. M. Driscoll, BMC
Mol. Biol., 2013, 14, 12.
17 M. E. Budiman, J. L. Bubenik, A. C. Miniard, L. M.
Middleton, C. A. Gerber, A. Cash and D. M. Driscoll, Mol.
Cell, 2009, 35, 479–489.
18 A. C. Miniard, L. M. Middleton, M. E. Budiman, C. A.
Gerber and D. M. Driscoll, Nucleic Acids Res., 2010, 38,
4807–4820.
19 M. J. Bro¨cker, J. M. L. Ho, G. M. Church, D. So¨ll and
P. O’Donoghue, Angew. Chem., Int. Ed., 2014, 53, 319–323.
20 E. K. Wirth, M. Conrad, J. Winterer, C. Wozny, B. A.
Carlson, S. Roth, D. Schmitz, G. W. Bornkamm,
V. Coppola, L. Tessarollo, L. Schomburg, J. Ko¨hrle, D. L.
Hatfield and U. Schweizer, FASEB J., 2010, 24, 844–852.
21 E. K. Wirth, B. S. Bharathi, D. Hatfield, M. Conrad,
M. Brielmeier and U. Schweizer, Biol. Trace Elem. Res.,
2014, 158, 203–210.
22 S. Seeher, B. A. Carlson, A. C. Miniard, E. K. Wirth,
Y. Mahdi, D. L. Hatfield, D. M. Driscoll and U. Schweizer,
Biochem. J., 2014, 462, 67–75.
23 O. Agamy, B. Ben Zeev, D. Lev, B. Marcus, D. Fine, D. Su,
G. Narkis, R. Ofir, C. Hoﬀmann, E. Leshinsky-Silver,
H. Flusser, S. Sivan, D. So¨ll, T. Lerman-Sagie and O. S. Birk,
Am. J. Hum. Genet., 2010, 87, 538–544.
24 X.-M. Xu, A. A. Turanov, B. A. Carlson, M.-H. Yoo, R. A.
Everley, R. Nandakumar, I. Sorokina, S. P. Gygi, V. N.
Gladyshev and D. L. Hatfield, Proc. Natl. Acad. Sci. U. S. A.,
2010, 107, 21430–21434.
25 R. Tobe, S. Naranjo-Suarez, R. A. Everley, B. A. Carlson, A. A.
Turanov, P. A. Tsuji, M.-H. Yoo, S. P. Gygi, V. N. Gladyshev and
D. L. Hatfield, J. Biol. Chem., 2013, 288, 14709–14715.
26 L. Schomburg and U. Schweizer, Biochim. Biophys. Acta,
Gen. Subj., 2009, 1790, 1453–1462.
27 R. Sunde, in Selenium – Its molecular biology and role in
human health, ed. D. L. Hatfield, M. Berry and V. N.
Gladyshev, Springer, 2012, pp. 137–152.
28 M. T. Howard, B. A. Carlson, C. B. Anderson and D. L.
Hatfield, J. Biol. Chem., 2013, 288, 19401–19413.
29 A. Seyedali and M. J. Berry, RNA, 2014, 20, 1248–1256.
30 J. Y. Kim, B. A. Carlson, X.-M. Xu, Y. Zeng, S. Chen, V. N.
Gladyshev, B. J. Lee and D. L. Hatfield, Biochem. Biophys.
Res. Commun., 2011, 409, 814–819.
31 B. A. Zachara, H. Pawluk, E. Bloch-Boguslawska, K. M.
Sliwka, J. Korenkiewicz, Z. Skok and K. Ryc´, Arch. Environ.
Health, 2001, 56, 461–466.
32 D. Behne and W. Wolters, J. Nutr., 1983, 113, 456–461.
33 M. Haratake, K. Koga, M. Inoue, T. Fuchigami and
M. Nakayama, Metallomics, 2011, 3, 1019–1026.
34 M. Ku¨hbacher, J. Bartel, B. Hoppe, D. Alber, G. Bukalis,
A. U. Bra¨uer, D. Behne and A. Kyriakopoulos, J. Neurochem.,
2009, 110, 133–142.
35 M. Ku¨hbacher, J. Bartel, D. Alber, G. Bukalis and H.
Ku¨hn, 2014, http://www.laborjournal.de/editorials/ed424/
Ms421_v425_web.pdf, accessed 11 May 2015.
36 P. Ramos, A. Santos, N. R. Pinto, R. Mendes, T. Magalha˜es
and A. Almeida, Biol. Trace Elem. Res., 2014, 163, 89–96.
37 L. R. Ferguson, N. Karunasinghe, S. Zhu and A. H. Wang,
Mutat. Res., 2012, 733, 100–110.
38 S. P. Shetty, R. Shah and P. R. Copeland, J. Biol. Chem.,
2014, 289, 25317–25326.
39 G. Ballihaut, L. E. Kilpatrick, E. L. Kilpatrick and W. C.
Davis, Metallomics, 2012, 4, 533–538.
40 R. F. Burk, K. E. Hill, A. K. Motley, V. P. Winfrey, S. Kurokawa,
S. L. Mitchell and W. Zhang, FASEB J., 2014, 28, 3579–3588.
41 A. E. Clatworthy, W. Stockinger, R. H. Christie, W. J.
Schneider, J. Nimpf, B. T. Hyman and G. W. Rebeck,
Neuroscience, 1999, 90, 903–911.
42 S. Kurokawa, K. E. Hill, W. H. McDonald and R. F. Burk,
J. Biol. Chem., 2012, 287, 28717–28726.
43 G. E. Olson, V. P. Winfrey, S. K. NagDas, K. E. Hill and
R. F. Burk, J. Biol. Chem., 2007, 282, 12290–12297.
44 M. W. Pitts, A. V. Raman, A. C. Hashimoto, C. Todorovic,
R. A. Nichols and M. J. Berry, Neuroscience, 2012, 208, 58–68.
45 I. Masiulis, T. A. Quill, R. F. Burk and J. Herz, Biol. Chem.,
2009, 390, 67–73.
46 S. W. Caito, D. Milatovic, K. E. Hill, M. Aschner, R. F. Burk
and W. M. Valentine, Brain Res., 2011, 1398, 1–12.
47 R. F. Burk, G. E. Olson, K. E. Hill, V. P. Winfrey, A. K.
Motley and S. Kurokawa, FASEB J., 2013, 27, 3249–3256.
48 H. Steinbrenner, L. Alili, E. Bilgic, H. Sies and P. Brenneisen,
Free Radical Biol. Med., 2006, 40, 1513–1523.
49 M. Scharpf, U. Schweizer, T. Arzberger, W. Roggendorf,
L. Schomburg and J. Ko¨hrle, J. Neural Transm., 2007, 114,
877–884.
Critical Review Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Metallomics, 2015, 7, 1213--1228 | 1225
50 F. P. Bellinger, A. V. Raman, R. H. Rueli, M. T. Bellinger,
A. S. Dewing, L. A. Seale, M. A. Andres, J. H. Uyehara-Lock,
L. R. White, G. W. Ross and M. J. Berry, J. Parkinson’s Dis.,
2012, 2, 115–126.
51 A. V. Raman, M. W. Pitts, A. Seyedali, A. C. Hashimoto,
L. A. Seale, F. P. Bellinger and M. J. Berry, Genes, Brain
Behav., 2012, 11, 601–613.
52 C. N. Byrns, M. W. Pitts, C. A. Gilman, A. C. Hashimoto and
M. J. Berry, J. Biol. Chem., 2014, 289, 9662–9674.
53 K.-M. Fang, F.-C. Cheng, Y.-L. Huang, S.-Y. Chung,
Z.-Y. Jian and M.-C. Lin, Biol. Trace Elem. Res., 2013, 152,
66–74.
54 P. Bitencourt, L. Belle, G. Bonfanti, L. Cargnelutti,
K. D. Bona, P. Silva, F. Abdalla, R. Zanette, R. Guerra,
C. Funchal and M. Moretto, Hum. Exp. Toxicol., 2013, 32,
942–949.
55 M. Nazırog˘lu, O¨. Çelik, A. C. Ug˘uz and A. Bu¨tu¨n, Biol. Trace
Elem. Res., 2015, 164, 72–79.
56 I. Ben Amara, H. Fetoui, F. Guermazi and N. Zeghal, Int.
J. Dev. Neurosci., 2009, 27, 719–726.
57 A. S. Abedelhaﬀez and A. Hassan, Acta Physiol. Hung., 2013,
100, 197–210.
58 O. L. Adebayo, G. A. Adenuga and R. Sandhir, Nutr. Neurosci.,
2014, 17, 268–278.
59 A. C. Ug˘uz and M. Nazırog˘lu, Neurochem. Res., 2012, 37,
1631–1638.
60 M. Nazırog˘lu, N. S- enol, V. Ghazizadeh and V. Yu¨ru¨ker, Cell.
Mol. Neurobiol., 2014, 34, 895–903.
61 N. Mendelev, S. L. Mehta, S. Witherspoon, Q. He, J. Z.
Sexton and P. A. Li, Mitochondrion, 2011, 11, 76–82.
62 S. L. Mehta, N. Mendelev, S. Kumari and P. Andy Li, Int.
J. Biochem. Cell Biol., 2013, 45, 604–611.
63 S. Kumari, S. L. Mehta and P. A. Li, PLoS One, 2012,
7, e39382.
64 A. S. de Freitas and J. B. T. Rocha, Neurosci. Lett., 2011, 503,
1–5.
65 A. P. Ardais, G. G. Viola, M. S. Costa, F. Nunes, G. A. Behr,
F. Klamt, J. C. F. Moreira, D. O. Souza, J. B. T. Rocha and
L. O. Porciu´ncula, Toxicol. Sci., 2010, 113, 434–443.
66 N. L. Chanaday, A. F. de Bem and G. A. Roth, Neurochem.
Int., 2011, 59, 1155–1162.
67 G. Roseni Mundstock Dias, R. Medeiros Golombieski,
R. de Lima Portella, G. Pires do Amaral, F. Antunes Soares,
J. B. Teixeira da Rocha, C. Wayne Nogueira and N. Vargas
Barbosa, Neuroendocrinology, 2014, 100, 45–59.
68 C. A. Bru¨ning, B. M. Gai, S. M. Soares, F. Martini and C. W.
Nogueira, Pharmacol., Biochem. Behav., 2014, 125, 15–20.
69 P. M. Chagas, S. G. Rosa, M. H. M. Sari, C. E. S. Oliveira,
R. F. S. Canto, S. C. A. da Luz, A. L. Braga and C. W.
Nogueira, Pharmacol., Biochem. Behav., 2014, 118, 87–95.
70 I. Musik, M. Kiełczykowska and J. Kocot, BioMetals, 2013,
26, 763–771.
71 S. M. Barayuga, X. Pang, M. A. Andres, J. Panee and
F. P. Bellinger, Neurotoxicology, 2013, 37, 240–246.
72 E. Song, C. Su, J. Fu, X. Xia, S. Yang, C. Xiao, B. Lu, H. Chen,
Z. Sun, S. Wu and Y. Song, Life Sci., 2014, 109, 37–43.
73 T. Garcia, J. L. Esparza, M. R. Nogue´s, M. Romeu,
J. L. Domingo and M. Go´mez, Hippocampus, 2010, 20,
218–225.
74 S. Zhang, C. Rocourt and W.-H. Cheng, Mech. Ageing Dev.,
2010, 131, 253–260.
75 P. A. Mitozo, L. F. de Souza, G. Loch-Neckel, S. Flesch,
A. F. Maris, C. P. Figueiredo, A. R. S. dos Santos, M. Farina
and A. L. Dafre, Free Radical Biol. Med., 2011, 51, 69–77.
76 M.-H. Yoo, X. Gu, X.-M. Xu, J. Y. Kim, B. A. Carlson,
A. D. Patterson, H. Cai, V. N. Gladyshev and D. L.
Hatfield, Antioxid. Redox Signaling, 2010, 12, 819–827.
77 M. W. Pitts, C. N. Byrns, A. N. Ogawa-Wong, P. Kremer and
M. J. Berry, Biol. Trace Elem. Res., 2014, 161, 231–245.
78 N. E. Savaskan, A. Borchert, A. U. Bra¨uer and H. Kuhn, Free
Radical Biol. Med., 2007, 43, 191–201.
79 D. N. Hauser, A. A. Dukes, A. D. Mortimer and T. G.
Hastings, Free Radical Biol. Med., 2013, 65, 419–427.
80 J. R. Godoy, M. Funke, W. Ackermann, P. Haunhorst,
S. Oesteritz, F. Capani, H. P. Elsasser and C. H. Lillig,
Biochim. Biophys. Acta, 2011, 1810, 2–92.
81 D. Silva-Adaya, M. E. Gonsebatt and J. Guevara, Oxid. Med.
Cell. Longevity, 2014, 2014, 1–13.
82 A. P. Kudin, B. Augustynek, A. K. Lehmann, R. Kova´cs and
W. S. Kunz, Biochim. Biophys. Acta, Bioenerg., 2012, 1817,
1901–1906.
83 M. Cohen-Kutner, L. Khomsky, M. Trus, H. Ben-Yehuda,
J. M. Lenhard, Y. Liang, T. Martin and D. Atlas, Redox Biol.,
2014, 2, 447–456.
84 P. Lopert, B. J. Day and M. Patel, PLoS One, 2012, 7, e50683.
85 J. H. Ahn, J. H. Choi, J. M. Song, C. H. Lee, K.-Y. Yoo,
I. K. Hwang, J. S. Kim, H.-C. Shin and M. H. Won, Exp.
Gerontol., 2011, 46, 946–952.
86 H. Esen, F. Erdi, B. Kaya, B. Feyzioglu, F. Keskin and
L. S. Demir, J. Neuro-Oncol., 2014, 121, 451–458.
87 L. V. Papp, J. Lu, A. Holmgren and K. K. Khanna, Antioxid.
Redox Signaling, 2007, 9, 775–806.
88 R. F. Burk and K. E. Hill, Annu. Rev. Nutr., 2005, 25, 215–235.
89 Y. Zhang and V. N. Gladyshev, PLoS Genet., 2008,
4, e1000095.
90 A. Dikiy, S. V. Novoselov, D. E. Fomenko, A. Sengupta,
B. A. Carlson, R. L. Cerny, K. Ginalski, N. V. Grishin, D. L.
Hatfield and V. N. Gladyshev, Biochemistry, 2007, 46,
6871–6882.
91 F. Musiani, S. Ciurli and A. Dikiy, J. Proteome Res., 2011, 10,
968–976.
92 M. E. Moustafa and H. A. Antar, Biochem. Genet., 2012, 50,
736–747.
93 F. Li, P. B. Lutz, Y. Pepelyayeva, E. S. J. Arne´r, C. A. Bayse
and S. Rozovsky, Proc. Natl. Acad. Sci. U. S. A., 2014, 111,
6976–6981.
94 S.-J. Han, B. C. Lee, S. H. Yim, V. N. Gladyshev and
S.-R. Lee, PLoS One, 2014, 9, e95518.
95 S. Guariniello, G. Colonna, R. Raucci, M. Costantini, G. Di
Bernardo, F. Bergantino, G. Castello and S. Costantini,
Biochim. Biophys. Acta, Proteins Proteomics, 2014, 1844,
447–456.
Metallomics Critical Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1226 | Metallomics, 2015, 7, 1213--1228 This journal is©The Royal Society of Chemistry 2015
96 A. D. Ferguson, V. M. Labunskyy, D. E. Fomenko, D. Araç,
Y. Chelliah, C. A. Amezcua, J. Rizo, V. N. Gladyshev and
J. Deisenhofer, J. Biol. Chem., 2006, 281, 3536–3543.
97 J. L. Martin, Structure, 1995, 3, 245–250.
98 M. W. Pitts, M. A. Reeves, A. C. Hashimoto, A. Ogawa,
P. Kremer, L. A. Seale and M. J. Berry, J. Biol. Chem., 2013,
288, 26121–26134.
99 M. A. Reeves, F. P. Bellinger and M. J. Berry, Antioxid. Redox
Signaling, 2010, 12, 809–818.
100 S. Y. Yim, K. R. Chae, S. B. Shim, J. T. Hong, J. Y. Park,
C. Y. Lee, H. J. Son, Y. Y. Sheen and D. Y. Hwang, Int. J. Mol.
Med., 2009, 24, 91–96.
101 P. Chen, R.-R. Wang, X.-J. Ma, Q. Liu and J.-Z. Ni,
Int. J. Mol. Sci., 2013, 14, 4385–4399.
102 Y. Kim, J. S. Goo, I. Y. Kim, J. E. Kim, M. H. Kwak, J. Go,
S. Shim, J. T. Hong, D. Y. Hwang and J. K. Seong, Int. J. Mol.
Med., 2014, 34, 1688–1698.
103 X. Qiao, J. Tian, P. Chen, C. Wang, J. Ni and Q. Liu, Int.
J. Mol. Sci., 2013, 14, 22233–22245.
104 S. C. Starossom, I. D. Mascanfroni, J. Imitola, L. Cao,
K. Raddassi, S. F. Hernandez, R. Bassil, D. O. Croci,
J. P. Cerliani, D. Delacour, Y. Wang, W. Elyaman, S. J.
Khoury and G. A. Rabinovich, Immunity, 2012, 37, 249–263.
105 K. Kajitani, Y. Kobayakawa, H. Nomaru, T. Kadoya, H. Horie
and Y. Nakabeppu, NeuroReport, 2014, 25, 171–176.
106 J.-L. Li, H.-F. Ruan, H.-X. Li, S. Li, S.-W. Xu and Z.-X. Tang,
Mol. Biol. Rep., 2010, 38, 4015–4022.
107 B.-R. Ou, M.-J. Jiang, C.-H. Lin, Y.-C. Liang, K.-J. Lee and
J.-Y. Yeh, BioMetals, 2011, 24, 323–333.
108 J.-L. Li, H.-X. Li, S. Li, X.-J. Gao, S.-W. Xu and Z.-X. Tang,
BioMetals, 2012, 25, 459–468.
109 I. J. Cajigas, G. Tushev, T. J. Will, S. T. Dieck, N. Fuerst and
E. M. Schuman, Neuron, 2012, 74, 453–466.
110 A. V. Raman, M. W. Pitts, A. Seyedali, A. C. Hashimoto,
F. P. Bellinger and M. J. Berry, Brain Behav., 2013, 3, 562–574.
111 F. Rage, N. Boulisfane, K. Rihan, H. Neel, T. Gostan,
E. Bertrand, R. Bordonne and J. Soret, RNA, 2013, 19,
1755–1766.
112 W. Xiao-Long, Y. Chuan-Ping, X. Kai and Q. Ou-Jv, Biochemistry,
2010, 75, 201–207.
113 Y. Zhang, Y. Zhou, U. Schweizer, N. E. Savaskan, D. Hua,
J. Kipnis, D. L. Hatfield and V. N. Gladyshev, J. Biol. Chem.,
2008, 283, 2427–2438.
114 N. Fradejas, M. Del Carmen Serrano Pe´rez, P. Tranque and
S. Calvo, Glia, 2011, 59, 959–972.
115 L. X. Liu, X. Y. Zhou, C. S. Li, L. Q. Liu, S. Y. Huang and
S. N. Zhou, J. Neurol. Sci., 2013, 34, 1671–1678.
116 A. A. Turanov, V. A. Shchedrina, R. A. Everley, A. V.
Lobanov, S. H. Yim, S. M. Marino, S. P. Gygi, D. L.
Hatfield and V. N. Gladyshev, Biochem. J., 2014, 462, 555–565.
117 X. A. Du, H. M. Wang, X. X. Dai, Y. Kou, R. P. Wu, Q. Chen,
J. L. Cao, X. Y. Mo and Y. M. Xiong, Osteoarthritis and
Cartilage, 2015, 23, 210–216.
118 S. V. Novoselov, G. V. Kryukov, X.-M. Xu, B. A. Carlson,
D. L. Hatfield and V. N. Gladyshev, J. Biol. Chem., 2007,
282, 11960–11968.
119 R. T. Y. Wu, L. Cao, B. P. C. Chen and W.-H. Cheng, J. Biol.
Chem., 2014, 289, 34378–34388.
120 P. H. Reddy, Brain Res., 2011, 1415, 136–148.
121 P. Mao and P. H. Reddy, Biochim. Biophys. Acta, Mol. Basis
Dis., 2011, 1812, 1359–1370.
122 Y. Yoshiyama, V. M. Y. Lee and J. Q. Trojanowski,
J. Neurol., Neurosurg. Psychiatry, 2013, 84, 784–795.
123 R. H. Swerdlow, J. M. Burns and S. M. Khan, Biochim.
Biophys. Acta, Mol. Basis Dis., 2014, 1842, 1219–1231.
124 A. Picco, M. C. Polidori, M. Ferrara, R. Cecchetti, D. Arnaldi,
M. Baglioni, S. Morbelli, P. Bastiani, I. Bossert, G. Fiorucci,
A. Brugnolo, M. E. Dottorini, F. Nobili and P. Mecocci, Eur.
J. Nucl. Med. Mol. Imaging, 2013, 41, 764–775.
125 S. Haider, S. Saleem, T. Perveen, S. Tabassum, Z. Batool,
S. Sadir, L. Liaquat and S. Madiha, Age, 2014, 36, 1291–1302.
126 B. R. Cardoso, V. Silva Bandeira, W. Jacob-Filho and S. M.
Franciscato Cozzolino, J. Trace Elem. Med. Biol., 2014, 28,
422–426.
127 B. R. Cardoso, T. P. Ong, W. Jacob-Filho, O. Jaluul,
M. I. D. A. A´. Freitas and S. M. F. Cozzolino, Br. J. Nutr.,
2010, 103, 803–806.
128 R. Gonza´lez-Domı´nguez, T. Garcı´a-Barrera and J. L. Go´mez-
Ariza, BioMetals, 2014, 27, 539–549.
129 M. G. M. Olde Rikkert, F. R. Verhey, J. W. C. Sijben,
F. H. Bouwman, P. L. J. Dautzenberg, M. Lansink,
W. M. W. Sipers, D. Z. B. van Asselt, A. M. J. van Hees,
M. Stevens, B. Vellas and P. Scheltens, J. Alzheimer’s Dis.,
2014, 41, 261–271.
130 H. Vural, H. Demirin, Y. Kara, I. Eren and N. Delibas,
J. Trace Elem. Med. Biol., 2010, 24, 169–173.
131 P. Scheltens, P. J. G. H. Kamphuis, F. R. J. Verhey, M. G. M.
Olde Rikkert, R. J. Wurtman, D. Wilkinson, J. W. R. Twisk
and A. Kurz, Alzheimer’s Dementia, 2010, 6, 1–10.e11.
132 E. Kesse-Guyot, L. Fezeu, C. Jeandel, M. Ferry, V. Andreeva,
H. Amieva, S. Hercberg and P. Galan, Am. J. Clin. Nutr.,
2011, 94, 892–899.
133 B. R. Cardoso, D. Apolina´rio, V. da Silva Bandeira, A. L.
Busse, R. M. Magaldi, W. Jacob-Filho and S. M. F.
Cozzolino, Eur. J. Nutr., 2015, 1–10, DOI: 10.1007/s00394-
014-0829-2.
134 M. Haratake, S. Yoshida, M. Mandai, T. Fuchigami and
M. Nakayama, Metallomics, 2013, 5, 479–483.
135 J. van Eersel, Y. D. Ke, X. Liu, F. Delerue, J. J. Kril, J. Go¨tz
and L. M. Ittner, Proc. Natl. Acad. Sci. U. S. A., 2010, 107,
13888–13893.
136 N. M. Corcoran, D. Martin, B. Hutter-Paier, M. Windisch,
T. Nguyen, L. Nheu, L. E. Sundstrom, A. J. Costello and
C. M. Hovens, J. Clin. Neurosci., 2010, 17, 1025–1033.
137 T. Ishrat, K. Parveen, M. M. Khan, G. Khuwaja, M. B. Khan,
S. Yousuf, A. Ahmad, P. Shrivastav and F. Islam, Brain Res.,
2009, 1281, 117–127.
138 A.-R. Gwon, J.-S. Park, J.-H. Park, S.-H. Baik, H.-Y. Jeong,
D.-H. Hyun, K. W. Park and D.-G. Jo, Neurosci. Lett., 2010,
469, 391–395.
139 G. Song, Z. Zhang, L. Wen, C. Chen, Q. Shi, Y. Zhang, J. Ni
and Q. Liu, J. Alzheimer’s Dis., 2014, 41, 85–99.
Critical Review Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Metallomics, 2015, 7, 1213--1228 | 1227
140 S. Pinton, C. A. Bru¨ning, C. E. Sartori Oliveira, M. Prigol
and C. W. Nogueira, J. Nutr. Biochem., 2013, 24, 311–317.
141 Z. Wang, Y. Wang, W. Li, F. Mao, Y. Sun, L. Huang and
X. Li, ACS Chem. Neurosci., 2014, 5, 952–962.
142 F. P. Bellinger, Q. P. He, M. T. Bellinger and Y. Lin,
J. Alzheimer’s Dis., 2008, 15, 465–472.
143 R. H. L. H. Rueli, A. C. Parubrub, A. S. T. Dewing,
A. C. Hashimoto, M. T. Bellinger, E. J. Weeber, J. H.
Uyehara-Lock, L. R. White, M. J. Berry and F. P.
Bellinger, J. Alzheimer’s Dis., 2015, 44, 379–383.
144 X. Du, H. Li, Z. Wang, S. Qiu, Q. Liu and J. Ni, Metallomics,
2013, 5, 861–870.
145 X. Du, Z. Wang, Y. Zheng, H. Li, J. Ni and Q. Liu, Inorg.
Chem., 2014, 53, 1672–1678.
146 X. Du, Y. Zheng, Z. Wang, Y. Chen, R. Zhou, G. Song, J. Ni
and Q. Liu, Inorg. Chem., 2014, 53, 11221–11230.
147 X. Du, S. Qiu, Z. Wang, R. Wang, C. Wang, J. Tian and
Q. Liu, Int. J. Mol. Sci., 2014, 15, 10199–10214.
148 G. M. Halliday, A. Ophof, M. Broe, P. H. Jensen, E. Kettle,
H. Fedorow, M. I. Cartwright, F. M. Griﬃths, C. E.
Shepherd and K. L. Double, Brain, 2005, 128, 2654–2664.
149 S. Ayton, P. Lei, J. A. Duce, B. X. W. Wong, A. Sedjahtera,
P. A. Adlard, A. I. Bush and D. I. Finkelstein, Ann. Neurol.,
2013, 73, 554–559.
150 D. J. Hare, P. Lei, S. Ayton, B. R. Roberts, R. Grimm, J. L.
George, D. P. Bishop, A. D. Beavis, S. J. Donovan, G. McColl,
I. Volitakis, C. L. Masters, P. A. Adlard, R. A. Cherny, A. I. Bush,
D. I. Finkelstein and P. A. Doble, Chem. Sci., 2014, 5, 2160.
151 L. Zecca, A. Stroppolo, A. Gatti, D. Tampellini, M. Toscani,
M. Gallorini, G. Giaveri, P. Arosio, P. Santambrogio and
R. G. Fariello, Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 9843.
152 D. Hare, S. Ayton, A. Bush and P. Lei, Front. Aging Neurosci.,
2013, 5, 34.
153 C. Venkateshappa, G. Harish, R. B. Mythri, A. Mahadevan,
M. M. S. Bharath and S. K. Shankar, Neurochem. Res., 2011,
37, 358–369.
154 G. S. Gaki and A. G. Papavassiliou, NeuroMol. Med., 2014,
16, 217–230.
155 A. Recasens and B. Dehay, Front. Neuroanat., 2014, 8, a159.
156 A. Shahar, K. V. Patel, R. D. Semba, S. Bandinelli,
D. R. Shahar, L. Ferrucci and J. M. Guralnik, Mov. Disord.,
2010, 25, 1909–1915.
157 S. Younes-Mhenni, M. Aissi, N. Mokni, A. Boughammoura-
Bouatay, S. Chebel, M. Frih-Ayed, A. Kerkeni, M. Bost,
G. Chazot, M. T. Sfar and M. H. Sfar, Tunis. Med., 2013,
91, 402–405.
158 L. K. Mischley, J. Allen and R. Bradley, J. Neurol. Sci., 2012,
318, 72–75.
159 G. F. Combs, Br. J. Nutr., 2001, 85, 517–547.
160 H.-W. Zhao, J. Lin, X.-B. Wang, X. Cheng, J.-Y. Wang, B.-L.
Hu, Y. Zhang, X. Zhang and J.-H. Zhu, PLoS One, 2013,
8, e83060.
161 M. L. Vizuete, V. Steﬀen, A. Machado and J. Cano, Eur.
J. Pharmacol., 1994, 270, 183–187.
162 H.-C. Kim, W.-K. Jhoo, E.-J. Shin and G. Bing, Brain Res.,
2000, 862, 247–252.
163 D. J. Hare, P. A. Adlard, P. A. Doble and D. I. Finkelstein,
Metallomics, 2013, 5, 91–109.
164 H. A. Khan, Neurochem. Int., 2010, 57, 489–491.
165 J. H. Ellwanger, P. Molz, D. R. Dallemole, A. Pereira Dos
Santos, T. E. Muller, L. Cappelletti, M. Goncalves da Silva,
S. I. Rech Franke, D. Pra and J. A. Pegas Henriques,
Nutrition, 2015, 31, 359–365.
166 F. P. Bellinger, M. T. Bellinger, L. A. Seale, A. S. Takemoto,
A. V. Raman, T. Miki, A. B. Manning-Bog˘, M. J. Berry,
L. R. White and G. W. Ross, Mol. Neurodegener., 2011, 6, 8.
167 R. Gandhi, A. Laroni and H. L. Weiner, J. Neuroimmunol.,
2010, 221, 7–14.
168 B. Broux, P. Stinissen and N. Hellings, Crit. Rev. Immunol.,
2013, 33, 283–306.
169 G. G. Ortiz, F. P. Pacheco-Moise´s, M. A´. Macı´as-Islas,
L. J. Flores-Alvarado, M. A. Mireles-Ramı´rez, E. D. Gonza´lez-
Renovato, V. E. Herna´ndez-Navarro, A. L. Sa´nchez-Lo´pez and
M. A. Alatorre-Jime´nez, Arch. Med. Res., 2014, 45, 687–697.
170 S. Ljubisavljevic, I. Stojanovic, T. Cvetkovic, S. Vojinovic,
D. Stojanov, D. Stojanovic, V. Bojanic, D. Stokanovic and
D. Pavlovic, NeuroImmunoModulation, 2014, 21, 13–20.
171 I. Tasset, E. Agu¨era, F. Sa´nchez-Lo´pez, M. Feijo´o, A. I.
Giraldo, A. H. Cruz, F. Gasco´n and I. Tu´nez, Clin. Biochem.,
2012, 45, 440–444.
172 T. Rosenling, M. P. Stoop, A. Attali, H. van Aken, E. Suidgeest,
C. Christin, C. Stingl, F. Suits, P. Horvatovich, R. Q. Hintzen,
T. Tuinstra, R. Bischoﬀ and T. M. Luider, J. Proteome Res.,
2012, 11, 2048–2060.
173 M. Mehrpour, A. Kyani, M. Tafazzoli, F. Fathi and M. T.
Joghataie, Magn. Reson. Chem., 2013, 51, 102–109.
174 K. Socha, J. Kochanowicz, E. Karpin´ska, J. Soroczyn´ska,
M. Jakoniuk, Z. Mariak and M. H. Borawska, Nutr. J., 2014,
13, 62.
175 L. P. Rowland and N. A. Shneider, N. Engl. J. Med., 2001,
344, 1688–1700.
176 A. W. Kilness and F. H. Hichberg, JAMA, J. Am. Med. Assoc.,
1977, 237, 2843–2844.
177 M. Vinceti, F. Bonvicini, K. J. Rothman, L. Vescovi and
F. Wang, Environ. Health, 2010, 9, 77.
178 M. Vinceti, D. Guidetti, M. Pinotti, S. Rovesti, M. Merlin,
L. Vescovi, M. Bergomi and G. Vivoli, Epidemiology, 1996, 7,
529–532.
179 M. Vinceti, N. Solovyev, J. Mandrioli, C. M. Crespi, F. Bonvicini,
E. Arcolin, E. Georgoulopoulou and B. Michalke, Neuro-
toxicology, 2013, 38, 25–32.
180 C. M. Weekley and H. H. Harris, Chem. Soc. Rev., 2013, 42,
8870–8894.
181 S. Kokarnig, A. Tsirigotaki, T. Wiesenhofer, V. Lackner,
K. A. Francesconi, S. A. Pergantis and D. Kuehnelt, J. Trace
Elem. Med. Biol., 2015, 29, 83–90.
182 O`. Palacios, J. R. Encinar, D. Schaumlo¨ﬀel and R. Lobinski,
Anal. Bioanal. Chem., 2006, 384, 1276–1283.
183 B. Michalke and A. Berthele, J. Anal. At. Spectrom., 2011, 26,
165–170.
184 W.-H. Li, Y.-C. Shi, I.-L. Tseng and V. H.-C. Liao, PLoS One,
2013, 8, e62387.
Metallomics Critical Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1228 | Metallomics, 2015, 7, 1213--1228 This journal is©The Royal Society of Chemistry 2015
185 T. Maraldi, M. Riccio, L. Zambonin, M. Vinceti, A. De Pol
and G. Hakim, Neurotoxicology, 2011, 32, 180–187.
186 K. L. Morgan, A. O. Estevez, C. L. Mueller, B. Cacho-
Valadez, A. Miranda-Vizuete, N. J. Szewczyk and
M. Estevez, Toxicol. Sci., 2010, 118, 530–543.
187 A. O. Estevez, K. L. Morgan, N. J. Szewczyk, D. Gems and
M. Estevez, Neurotoxicology, 2014, 41, 28–43.
188 A. O. Estevez, C. L. Mueller, K. L. Morgan, N. J. Szewczyk,
L. Teece, A. Miranda-Vizuete and M. Estevez, Neurotoxicol-
ogy, 2012, 33, 1021–1032.
189 J. P. Vonsattel, R. H. Myers, T. J. Stevens, R. J. Ferrante,
E. D. Bird and E. P. Richardson Jr., J. Neuropathol. Exp.
Neurol., 1985, 44, 559–577.
190 A. Bush, W. Pettingell, G. Multhaup, M. D. Paradis,
J. Vonsattel, J. Gusella, K. Beyreuther, C. Masters and
R. Tanzi, Science, 1994, 265, 1464–1467.
191 T.-C. Ju, H.-M. Chen, Y.-C. Chen, C.-P. Chang, C. Chang
and Y. Chern, Biochim. Biophys. Acta, Mol. Basis Dis., 2014,
1842, 1668–1680.
192 A. D. Ha and V. S. C. Fung, Curr. Opin. Neurol., 2012, 25,
491–498.
193 J. Paulsen, R. Ready, J. Hamilton, M. Mega and
J. Cummings, J. Neurol., Neurosurg. Psychiatry, 2001,
71, 310–314.
194 Z. Lu, E. Marks, J. Chen, J. Moline, L. Barrows,
M. Raisbeck, I. Volitakis, R. A. Cherny, V. Chopra,
A. I. Bush, S. Hersch and J. H. Fox, Neurobiol. Dis., 2014,
71C, 34–42.
195 C. F. Bortolatto, C. R. Jesse, E. A. Wilhelm, P. M. Chagas
and C. W. Nogueira, Neurotoxic. Res., 2012, 23, 214–224.
196 M. Birringer, S. Pilawa and L. Flohe´, Nat. Prod. Rep., 2002,
19, 693–718.
Critical Review Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 7
/5
/2
01
8 
3:
56
:4
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
